# Mayo Clinic: Phase 3 study closed enrollment, 118 enrolled (Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Mayo Clinic |
| Sponsor type | Academic and hospital |
| Study | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma |
| NCT ID | NCT06205316 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Biochemically Recurrent Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Recurrent Prostate Adenocarcinoma; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8 |
| Intervention types | drug, procedure, radiation, other |
| Target enrollment | 118 |
| Site countries | United States |
| Posted | 2024-01-16 |
| Planned start | 2024-04-04 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-17 |
| Last update posted | 2026-09-17 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 118 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06205316). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.